ClinicalTrials.gg
Active, not recruitingNCT04666038BRUIN CLL-321Updated Apr 24, 2026Results posted

Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

A Phase 3 interventional study of Pirtobrutinib and Idelalisib in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, sponsored by Loxo Oncology, Inc.. Active, not recruiting at 232 sites in 24 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-24.

Sponsored by Loxo Oncology, Inc. (part of Eli Lilly and Company) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
238
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell — 14 open to participants now, 19 under way, 6 of them phase 3. pirtobrutinib · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
9th of 23
238 · median 87
Started
2021
with 3 others
Phase 3
6 of 23
3 open now
Primary completion
2023-08
later than 0 of 18 live
Registered
2nd of 23
by date
Lead sponsor
6 of 23
Loxo Oncology, Inc.

Among the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by enrollment, is one of 4 that started in 2021, is one of 6 in phase 3, reaches primary completion later than 0 of the 18 other live ones, and was the 2nd registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

14 of the 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About pirtobrutinib

pirtobrutinib: first FDA approval 2023 (JAYPIRCA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing pirtobrutinib in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.

Read the detailed description

This is a Phase 3 global, randomized, open-label study comparing LOXO-305 (Arm A) to investigator's choice of either idelalisib plus rituximab or bendamustine plus rituximab (Arm B) in CLL/SLL patients who have been treated with at least a covalent BTK inhibitor (BTKi). Patients may have discontinued the prior covalent BTKi due to disease progression (PD) or intolerance. Patients who have received venetoclax are eligible for the study. Eligible patients will be randomized in 1:1 to Arm A or Arm B.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma

Keywords

  • Hematologic Disease
  • Lymphoma, non-Hodgkin's
  • Lymphoma, B-cell
  • Lymphoma
  • Bruton's tyrosine kinase inhibitor
  • Ibrutinib
  • Acalabrutinib
  • Zanubrutinib
  • Pirtobrutinib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed diagnosis of CLL/SLL requiring therapy as defined by iwCLL 2018 criteria.
  • Previously treated with a covalent BTK inhibitor.
  • (ECOG) 0-2.
  • ≥ 0.75 × 10\^9/L without granulocyte-colony-stimulating factor support, or ≥ 0.50 × 10\^9/L in patients with documented bone marrow involvement considered to impair hematopoiesis. Granulocyte-colony-stimulating factor support is permitted in patients with documented bone marrow involvement.
  • ≥ 8 g/dL or ≥ 6 g/dL in patients with documented bone marrow involvement considered to impair hematopoiesis. Transfusion support is permitted in patients with bone marrow involvement.
  • ≥ 50 × 10\^9/L. If an investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75 × 10\^9/L. Patients may enroll below these thresholds if the Investigator determines the cytopenia is related to bone marrow involvement considered to impair hematopoiesis. Patients with a platelet count \< 30 x 10\^9/L are excluded.
  • and ALT ≤ 3.0 x (ULN).
  • Total ≤ 1.5 x ULN.
  • Estimated of ≥ 30 mL/min.

Exclusion criteria

Exclusion Criteria:

  • Known or suspected Richter's transformation at any time preceding enrollment.
  • Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.
  • Ongoing drug-induced liver injury.
  • Active uncontrolled auto-immune cytopenia.
  • Significant cardiovascular disease.
  • History of allogeneic or stem cell transplantation (SCT) or chimeric antigen receptor-modified T cells (CAR-T) therapy within the past 60 days.
  • Active or .
  • Known active cytomegalovirus (CMV) infection.
  • Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.
  • Known (HIV) infection, regardless of .
  • active malabsorption syndrome or inflammatory bowel disease
  • Prior exposure to non-covalent (reversible) BTK inhibitor.
  • Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.
  • Current treatment with strong cytochrome P450 (CYP) 3A4 () inhibitors or inducers.
  • Vaccination with a within 28 days prior to randomization.
  • Patients with the following :

    1. Known hypersensitivity, including anaphylaxis, to any component or of LOXO-305. For patients planned to receive idelalisib, known hypersensitivity, including anaphylaxis, to any component or excipient of idelalisib. For patients planned to receive bendamustine, known hypersensitivity, including anaphylaxis, to any component or excipient of bendamustine.
    2. Prior significant hypersensitivity to rituximab.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
238 participants (actual)

Study arms

  • Experimental
    Arm A - Pirtobrutinib

    Participants received 200 milligrams (mg) of pirtobrutinib administered orally once daily (QD) on Days 1 through 28 of a 28-day cycle. The treatment was continued until progressive disease, a discontinuation criterion, or unacceptable toxicity.

    Drug: Pirtobrutinib

  • Active comparator
    Arm B - Idelalisib plus Rituximab or Bendamustine plus Rituximab

    Participants received either 150 mg of idelalisib administered twice-daily (BID) orally on Days 1 through 28 of a 28-day cycle in combination with 375 milligram per square meter (mg/m\^2) of rituximab by intravenous (IV) infusion on day 1 of cycle 1, then 4 IV infusions of rituximab 500 mg/m\^2 every 2 weeks (Q2W) and 3 IV infusions of rituximab 500 mg/m\^2 every 4 weeks (Q4W) or 70 mg/m\^2 of bendamustine administered IV on day 1 and 2 of each 28-day cycle from cycles 1 to 6 in combination with 375 mg/m\^2 of rituximab IV on day 1 of cycle 1, then 500 mg/m\^2 of rituximab on day 1 of each 28-day cycle from cycles 2 to 6.

    Drug: Idelalisib · Drug: Bendamustine · Drug: Rituximab

Interventions

  • Oral Pirtobrutinib

    Also known as: LOXO-305, LY3527727

  • Oral

    Also known as: Zydelig

  • IV

    Also known as: Treanda, Treakisym, Ribomustin, Levact

  • IV

    Also known as: Rituxan, MabThera, Truxima

06

What researchers measure

Primary outcomes

  1. Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

    PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an IRC according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018.

    Time frame: Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)

Secondary outcomes

  1. PFS Assessed by Investigator

    PFS is defined as time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an investigator according to iwCLL 2018.

    Time frame: Randomization to Disease Progression or Death Due to Any Cause (Up to 36 Months)

  2. Overall Survival (OS)

    OS was defined as time from randomization to death due to any cause.

    Time frame: Randomization to Death from Any Cause (Up to 36 months)

  3. Time to Next Treatment (TTNT)

    TTNT was defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), therapy of pirtobrutinib for Arm B patients, or death due to any cause, whichever occurs first.

    Time frame: Randomization to Subsequent Anticancer Therapy, Therapy of Pirtobrutinib or Death Due to Any Cause (Up to 36 Months)

  4. Event Free Survival (EFS)

    EFS is defined as the time from randomization to the first occurrence of: * Documented disease progression per iwCLL 2018 criteria as assessed by Investigator; or * Initiation of subsequent anticancer therapy for CLL/SLL; or * Unacceptable toxicity leading to treatment discontinuation as assessed by the Investigator; or * Death (due to any cause).

    Time frame: Randomization to Disease Progression, Subsequent Anticancer Therapy, Unacceptable Toxicity Leading to Treatment Discontinuation, or Death Due to Any Cause (Up to 36 Months)

  5. Percentage of Participants With Overall Response Rate (ORR) Assessed by Investigator

    ORR according to investigator-assessed best overall response (BOR) based on iwCLL 2018 is defined as the number of participants who achieve a BOR of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) at or before the initiation of subsequent anticancer therapy divided by the total number of participants randomized to each treatment arm.

    Time frame: Randomization to Subsequent Anticancer Therapy, Disease Progression or Death Due to Any Cause (Up to 36 Months)

  6. Time to Worsening (TTW) of CLL/SLL Related Symptoms

    TTW was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained patient-reported outcome (PRO) deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A \& Arm B - Idelalisib plus Rituximab) and up to Week 21 + Safety follow-up of up to 5 weeks (Arm B - Bendamustine plus Rituximab) assessment time point prior to disease progression.

    Time frame: Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab)

  7. Time to Worsening (TTW) of Physical Function

    Time of worsening was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained PRO deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A and IdelaR) and up to Week 21 + Safety follow-up (BR) assessment time point prior to disease progression.

    Time frame: Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab)

07

Results

Posted Mar 7, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Started119119
Received at least 1 dose of study drug116109
Completed00
Not completed119119
Withdrew: Progressive disease20
Withdrew: Death3832
Withdrew: Withdrawal by subject1019
Withdrew: Lost to follow-up02
Withdrew: On study treatment465
Withdrew: Off treatment on post-treatment-discontinuation follow-up2361

Outcome measures

PrimaryProgression-free Survival (PFS) Assessed by Independent Review Committee (IRC)

PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an IRC according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018.

Time frame:
Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)
Reported as:
Median · Months
Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)
MonthsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)13.96 (11.24 to 16.56)8.74 (8.08 to 10.38)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab · Log Rank · p = 0.0002 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.536 · 95% CI 0.385 to 0.746The Hazard Ratio (HR) \& 95% confidence interval (CI) were estimated from a stratified Cox proportional hazards model.
SecondaryPFS Assessed by Investigator

PFS is defined as time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an investigator according to iwCLL 2018.

Time frame:
Randomization to Disease Progression or Death Due to Any Cause (Up to 36 Months)
Reported as:
Median · Months
PFS Assessed by Investigator
MonthsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
PFS Assessed by Investigator15.28 (12.81 to 19.94)9.20 (7.33 to 10.64)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab · Log Rank · p = <0.0001 (The 2-sided nominal p-value was calculated based on a stratified log-rank test) · Hazard ratio (hr): 0.475 · 95% CI 0.338 to 0.669The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryOverall Survival (OS)

OS was defined as time from randomization to death due to any cause.

Time frame:
Randomization to Death from Any Cause (Up to 36 months)
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Overall Survival (OS)29.67 (27.10 to NA)NA (28.88 to NA)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab · Log Rank · p = 0.7202 (The 2-sided p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 1.090 · 95% CI 0.679 to 1.749The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryTime to Next Treatment (TTNT)

TTNT was defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), therapy of pirtobrutinib for Arm B patients, or death due to any cause, whichever occurs first.

Time frame:
Randomization to Subsequent Anticancer Therapy, Therapy of Pirtobrutinib or Death Due to Any Cause (Up to 36 Months)
Reported as:
Median · Months
Time to Next Treatment (TTNT)
MonthsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Time to Next Treatment (TTNT)23.95 (17.84 to 29.67)10.91 (8.74 to 12.48)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab · Log Rank · p = <0.0001 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.365 · 95% CI 0.254 to 0.524The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryEvent Free Survival (EFS)

EFS is defined as the time from randomization to the first occurrence of: * Documented disease progression per iwCLL 2018 criteria as assessed by Investigator; or * Initiation of subsequent anticancer therapy for CLL/SLL; or * Unacceptable toxicity leading to treatment discontinuation as assessed by the Investigator; or * Death (due to any cause).

Time frame:
Randomization to Disease Progression, Subsequent Anticancer Therapy, Unacceptable Toxicity Leading to Treatment Discontinuation, or Death Due to Any Cause (Up to 36 Months)
Reported as:
Median · Months
Event Free Survival (EFS)
MonthsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Event Free Survival (EFS)14.06 (11.40 to 16.95)7.62 (4.80 to 8.80)
Statistical analysis
  • Arm A - Pirtobrutinib vs Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab · Log Rank · p = <0.0001 (The 2-sided nominal p-value was calculated based on a stratified log-rank test.) · Hazard ratio (hr): 0.387 · 95% CI 0.280 to 0.534The HR and 95% CI were estimated from a stratified Cox proportional hazards model.
SecondaryPercentage of Participants With Overall Response Rate (ORR) Assessed by Investigator

ORR according to investigator-assessed best overall response (BOR) based on iwCLL 2018 is defined as the number of participants who achieve a BOR of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) at or before the initiation of subsequent anticancer therapy divided by the total number of participants randomized to each treatment arm.

Time frame:
Randomization to Subsequent Anticancer Therapy, Disease Progression or Death Due to Any Cause (Up to 36 Months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Response Rate (ORR) Assessed by Investigator
percentage of participantsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Percentage of Participants With Overall Response Rate (ORR) Assessed by Investigator66.4 (57.15 to 74.78)48.7 (39.47 to 58.07)
SecondaryTime to Worsening (TTW) of CLL/SLL Related Symptoms

TTW was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained patient-reported outcome (PRO) deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A \& Arm B - Idelalisib plus Rituximab) and up to Week 21 + Safety follow-up of up to 5 weeks (Arm B - Bendamustine plus Rituximab) assessment time point prior to disease progression.

Time frame:
Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab)
Reported as:
Median · Months
Time to Worsening (TTW) of CLL/SLL Related Symptoms
MonthsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Time to Worsening (TTW) of CLL/SLL Related SymptomsNA (NA to NA)NA (5.7 to NA)
SecondaryTime to Worsening (TTW) of Physical Function

Time of worsening was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms. The time to sustained PRO deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A and IdelaR) and up to Week 21 + Safety follow-up (BR) assessment time point prior to disease progression.

Time frame:
Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab)
Reported as:
Median · Months
Time to Worsening (TTW) of Physical Function
MonthsArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
Time to Worsening (TTW) of Physical FunctionNA (NA to NA)NA (5.7 to NA)

Adverse events

Collected over Baseline up to data cut-off date 29-August-2024 (up to 36 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A - Pirtobrutinib38/119 (31.9%)60/116 (51.7%)94/116 (81%)
Arm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab32/119 (26.9%)53/109 (48.6%)103/109 (94.5%)
Most frequent serious events
Showing 10 of 106
Most frequent serious events
EventArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
PneumoniaInfections and infestations20/11612/109
Covid-19Infections and infestations2/1166/109
Covid-19 pneumoniaInfections and infestations5/1164/109
Febrile neutropeniaBlood and lymphatic system disorders0/1164/109
DiarrhoeaGastrointestinal disorders0/1164/109
PyrexiaGeneral disorders2/1164/109
Vulval abscessInfections and infestations0/1161/32
Vaginal haemorrhageReproductive system and breast disorders1/340/109
ThrombocytopeniaBlood and lymphatic system disorders2/1163/109
Infusion related reactionInjury, poisoning and procedural complications0/1163/109
Most frequent other events
Showing 10 of 41
Most frequent other events
EventArm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus Rituximab
DiarrhoeaGastrointestinal disorders20/11630/109
PyrexiaGeneral disorders14/11628/109
FatigueGeneral disorders16/11627/109
NauseaGastrointestinal disorders13/11623/109
AnaemiaBlood and lymphatic system disorders21/11621/109
CoughRespiratory, thoracic and mediastinal disorders20/11620/109
NeutropeniaBlood and lymphatic system disorders21/11617/109
Neutrophil count decreasedInvestigations9/11619/109
VomitingGastrointestinal disorders7/11618/109
Covid-19Infections and infestations14/11618/109

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Arm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus RituximabTotal
Mean66.90 ± 9.3267.00 ± 8.5267.00 ± 8.91
Sex: Female, Male
Sex: Female, Male(Participants)Arm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus RituximabTotal
Female363672
Male8383166
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus RituximabTotal
Hispanic or Latino6410
Not Hispanic or Latino107108215
Unknown or Not Reported6713
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus RituximabTotal
American Indian or Alaska Native000
Asian141529
Native Hawaiian or Other Pacific Islander000
Black or African American156
White9895193
More than one race000
Unknown or Not Reported6410
Region of Enrollment
Region of Enrollment(participants)Arm A - PirtobrutinibArm B - Idelalisib Plus Rituximab or Bendamustine Plus RituximabTotal
Australia527
Austria112
Belgium101
Canada4610
China101424
Croatia011
Czechia213
France549
Germany246
Hungary347
Ireland213
Israel202
Italy231942
Japan303
Poland141731
Russia011
South Korea101
Spain426
Switzerland213
Taiwan011
Turkey112
United Kingdom14620
United States203353
08

Study locations

232 sites

Showing the first 100 of 232 sites across 24 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Loubert A, Creel K, Bhandari NR, Hess LM, Ruppert AS, Abada P, Regnault A, Payakachat N. Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. J Patient Rep Outcomes. 2026 Jun 22;10(1):109. doi: 10.1186/s41687-026-01126-w. PubMed 42329537 ↗
  • Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Matrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025 Aug;43(22):2538-2549. doi: 10.1200/JCO-25-00166. Epub 2025 Jun 6. PubMed 40479620 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2023, 29 months.

Results were first posted in Mar 2025, 1 year 6 months after primary completion. A results delay was requested in Aug 2024.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 29 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2020
First posted
Dec 14, 2020
StartActual
Mar 9, 2021
Primary completionActual
Aug 29, 2023
CompletionEst.
May 2027
Results delay requested
Aug 28, 2024
Results first posted
Mar 7, 2025
Last update
Apr 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04666038
Responsible party
Sponsor
First posted
Dec 14, 2020
Start date
Mar 9, 2021
Primary completion
Aug 29, 2023
Completion
May 2027 (estimated)
Results posted
Mar 7, 2025
Last update
Apr 24, 2026

Study contacts

Marisa Hill, MD
study director · Loxo Oncology, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirtobrutinib

Start the discussion